Recommended

Discover how to overcome low affinity or poor TCR yields that are slowing you down in this upcoming webinar – register your details today
Facing roadblocks in obesity drug discovery? Discover how integrated, validated strategies are helping teams accelerate development and reduce risk – register your details now
Unlock the science, strategy and real-world impact behind the next generation of precision therapies – access our new brand report now >>
Safety data is no longer just a regulatory checkbox – it’s a strategic advantage. Find out more in our upcoming webinar, register your details today
Explore how AI is reshaping early drug discovery, from target identification and compound screening to predictive modelling and trial design – register now!
news

Cannabinoid screening reveals anti-tumour properties of CBC and CBG

2.2K
SHARES
Share via

A high-throughput screening test of different cannabinoids has demonstrated that CBC and CBG exhibit anti-tumour effects.

CBC and CBG nest to cannabis leaf

A series of high-throughput screening (HTS) tests has revealed that the cannabinoids cannabichromene (CBC) and cannabigerol (CBG) both exhibit anti-tumour properties.

Using gastrointestinal cancer cells, researchers from Cannabics Pharmaceuticals screened the necrotic effects of a variety of cannabinoids on these cancer cells, as well as other cancer types previously tested.

Both CBC and CBG were shown to induce significantly higher rates of necrosis in these cancer cells compared to other cannabinoids.

 

Reserve your FREE place

 


Reduce preclinical failures with smarter off-target profiling

24 September 2025 | 15:00PM BST | FREE Webinar

Join this webinar to hear from Dr Emilie Desfosses as she shares insights into how in vitro and in silico methods can support more informed, human-relevant safety decisions -especially as ethical and regulatory changes continue to reshape preclinical research.

What you’ll learn:

  • Approaches for prioritizing follow-up studies and refining risk mitigation strategies
  • How to interpret hit profiles from binding and functional assays
  • Strategies for identifying organ systems at risk based on target activity modulation
  • How to use visualization tools to assess safety margins and compare compound profiles

Register Now – It’s Free!

 

Dr Yaakov Waksman, the company’s head of cannabidiol research, said: “My working assumption is that these results show that a correlation may exist between a cannabinoid’s topological polar surface area (TPSA) value and its ability to induce anti-tumour activity, diminishing cancer cell’s viability rates. CBC and CBG, as neutral cannabinoids, were both found to have a TPSA value which allows the cannabinoid molecule to penetrate a cancer cell’s membrane, whereas their acidic form (CBCA and CBGA) – do not. This could explain the difference in anti-tumour activity rates demonstrated.”

Dr Eyal Ballan, CTO and Co-Founder, commented: “We are intrigued by the results we have obtained in the lab and our aim is to consider placing an emphasis on this organ system and to further explore the differential anti-tumour properties of cannabinoids. We believe that these preliminary results vindicate our vision; which is to bring personalisation into cannabinoid-based cancer treatments.”